January 9, 2023

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment

PRESS RELEASE STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines for neurodevelopmental disorders and heralds the expansion of its portfolio into wider neuropsychiatric indications Geneva, SWITZERLAND – 9 January 2023, STALICLA

>

Taiwan welcomes first German parliamentarian delegation in 2023

A group of Free Democratic Party parliamentarians from Germany, led by the chair of the Bundestag Defense Committee, Marie-Agnes Strack-Zimmermann and the party’s deputy chair, Johannes Vogel, arrived in Taiwan on Monday, making them the first German d…

>